| HOME >> MEDICINE >> TECHNOLOGY |
$
428,299$
402,767COSTS AND EXPENSES (1):Cost of revenues
167,407156,719Cost of revenues – amortization of intangible assets
40,87739,240Cost of revenues – impairment of intangible assets
123,350-Research and development
27,25424,754Selling and marketing
61,89156,575General and administrative
37,47036,117Amortization of intangible assets
14,12912,854Litigation-related settlement benefit
(1,097)-Impairment of goodwill
76,723-Impairment of intangible assets
20,117-Acquired in-process research and development
2,000-Restructuring charges
885797571,006327,056(Loss) Income from operations
(142,707)75,711Interest income
371162Interest and other expense, net
(30,253)(32,423)(Loss) Income before provision for income taxes
(172,589)43,450(Benefit) provision for income taxes
(35,615)18,882Net (loss) income
$
(136,974)$
24,568Net (loss) income per share: Basic
$
(0.53)$
.10Diluted
$
(0.53)$
.09Weighted average number of shares outstanding:Basic
259,188257,038Diluted
259,188259,884(1) Stock-based compensation included in costs and expenses during the three months ended September 25, 2010 was $1,217 for cost of revenues, $1,065 for research and development, $1,736 for selling and marketing and $5,618 for general and administrative. Stock-based compensation included in costs and expenses during the three months ended September 26, 2009 was $897 for cost of revenues, $865 for research and development, $1,156 for selling and marketing and $5,668 for general and administrative.(2) Adjusted for the retrospective adoption of a new standard u
'/>"/>
| SOURCE Hologic, Inc. Copyright©2010 PR Newswire. All rights reserved |